Pharmacological studies with endogenous enhancer substances: β-phenylethylamine, tryptamine, and their synthetic derivatives

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 3, 2004, Pages 421-427

  Shimazu, Seiichiro ^a   Miklya, Ildikó ^b  

^a Fujimoto Pharmaceutical Corporation   (Japan)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Phenylethylamine (PEA); ( ) 1 (benzofuran 2 yl) 2 propylaminopentane; ( ) 1 (Benzofuran 2 yl) 2 propylaminopentane ( ) BPAP ; ( ) BPAP; ( ) Deprenyl (Selegiline); Enhancer regulation; Enhancer substances; MAO; Trace amines; Tryptamine

Indexed keywords

AMINE; MONOAMINE OXIDASE INHIBITOR; PHENETHYLAMINE; SELEGILINE; TRYPTAMINE;

ALZHEIMER DISEASE; BRAIN NERVE CELL; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG POTENCY; ELECTROSTIMULATION; ENHANCER REGION; HUMAN; MESENCEPHALON; PARKINSON DISEASE; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOFURANS; HUMANS; MESENCEPHALON; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; PHENETHYLAMINES; PSYCHOTROPIC DRUGS; SELEGILINE; TRYPTAMINES;

EID: 1842839793     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2003.11.016     Document Type: Review

References (66)

1. Allain H., Gougnard J., Naukirek H.C. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMP). Acta Neurol. Scand. 136:1991;73-78.
2. Amsterdam J.D. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J. Clin. Psychiatry. 64:2003;208-214.
3. Birkmayer W., Riederer P., Ambrozi L., Youdim M.B.H. Implications of combined treatment with "madopar" and L-deprenil in Parkinson's disease. Lancet. 1:1977;439-443.
4. Birkmayer W., Riederer P., Linauer W., Knoll J. L-Deprenyl plus L-phenylalanine in the treatment of depression. J. Neural Transm. 59:1984;81-87.
5. Bodkin J.A., Amsterdam J.D. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am. J. Psychiatry. 159:2002;1869-1875.
6. Borowsky B., Adham N., Jones K.A., Raddatz R., Artymyshyn R., Ogozalek K.L., Durkin M.M., Lakhlani P.P., Bonini J.A., Pathirana S., Boyle N., Pu X., Kouranova E., Lichtblau H., Ochoa F.Y., Branchek T.A., Gerald C. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 98:2001;8966-8971.
7. Boulton A.A., Juorio A.V., Downer R.G.H. Trace Amines: Comparative and Clinical Neurobiology (Experimental and Clinical Neuroscience). 1988;Humana Press, Totowa, NJ.
8. Bunzow J.R., Sonders M.S., Arttamangkul S., Harrison L.M., Zhang G., Quigley D.I., Darland T., Suchland K.L., Pasumamula S., Kennedy J.L., Olson S.B., Magenis R.E., Amara S.G., Grandy D.K. Amphetamine, 3,4- methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 60:2001;1181-1188.
9. Davis B.A., Boulton A.A. The trace amines and their acidic metabolites in depression - an overview. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 18:1994;17-45.
10. Greenshaw A.J. Functional interactions of 2-phenylethylamine and of tryptamine with brain catecholamines: implications for psychotherapeutic drug action. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 13:1989;431-443.
11. Hamabe W., Fujita R., Yasusa T., Yoneda F., Yoshida A., Ueda H. (-)1-(Benzofuran-2-yl)-2-propylaminopentane shows survival effect on cortical neurons under serum-free condition through sigma receptors. Cell. Mol. Neurobiol. 20:2000;695-702.
12. 3H] beta-phenylethylamine binding sites in rat brain. Eur. J. Pharmacol. 83:1982;147-148.
13. Janssen P.A., Leysen J.E., Megens A.A., Awouters F.H. Does phenylethylamine act as an endogenous amphetamine in some patients? Int. J. Neuropsychopharmacol. 2:1999;229-240.
14. Knoll J. Memories of my 45 years in research. Pharmacol. Toxicol. 75:1994;65-72.
15. Knoll J. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol. Toxicol. 82:1998;57-66.
16. Knoll J. Antiaging compounds: (-)Deprenyl (Selegiline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, (-)BPAP, a selective highly potent enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. CNS Drug Rev. 7:2001;317-345.
17. Knoll J. Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives. Neurochem. Res. 28:2003;1187-1209.
18. Knoll J., Magyar K. Some puzzling effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5:1972;393-408.
19. Knoll J., Miklya I. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication. Life Sci. 56:1995;611-620.
20. Knoll J., Vizi E.S., Somogyi G. Phenylisopropylmethylpropynilamine (E-250), a monoamine oxidase inhibitor antagonizing effects of tyramine. Arzneim.-Forsch. 18:1968;109-112.
21. Knoll J., Miklya I., Knoll B., Markó R., Kelemen K. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. Life Sci. 58:1996;817-827.
22. Knoll J., Knoll B., Miklya I. High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers. Life Sci. 58:1996;945-952.
23. Knoll J., Miklya I., Knoll B., Markó R., Rácz D. Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. Life Sci. 58:1996;2101-2114.
24. Knoll J., Yoneda F., Knoll B., Ohde H., Miklya I. (-)1-(Benzofuran-2-yl)- 2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Br. J. Pharmacol. 128:1999;1723-1732.
25. Knoll J., Miklya I., Knoll B., Yasusa T., Shimazu S., Yoneda F. 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged. Life Sci. 71:2002;1975-1984.
26. Knoll J., Miklya I., Knoll B. Stimulation of the catecholaminergic and serotoninergic neurons in the rat brain by R-(-)-1-(benzofuran-2-yl)-2- propylaminopentane, (-)-BPAP. Life Sci. 71:2002;2137-2144.
27. Kuhn W., Muller T. The clinical potential of deprenyl in neurologic and psychiatric disorders. J. Neural Transm., Suppl. 48:1996;85-93.
28. Larsen J.P., Boas J., Erdal J.E. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur. J. Neurol. 6:1999;539-547.
29. Lees A.J. Selegiline hydrochloride and cognition. Acta Neurol. Scand., Suppl. 136:1991;91-94.
30. Mann J.J., Gershon S. A selective monoamine oxidase-B inhibitor in endogenous depression. Life Sci. 26:1980;877-882.
31. Mayberg H.S., Solomon D.H. Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv. Neurol. 65:1995;49.
32. McGrath P.J., Stewart J.W., Harrison W., Wager S., Nunes E.N., Quitkin F.M. A placebo-controlled trial of L-deprenyl in atypical depression. Psychopharmacol. Bull. 25:1989;63-67.
33. Mendlewitz J., Youdim M.B.H. L-Deprenyl: a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double-blind evaluation. Br. J. Psychiatry. 142:1983;508-511.
34. Miklya I., Knoll J. Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Life Sci. 72:2003;2915-2921.
35. Miklya I., Knoll B., Knoll J. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (Selegiline), α-tocopherol was ineffective in the DATATOP study. Life Sci. 72:2003;2641-2648.
36. Miklya I., Knoll B., Knoll J. An HPLC tracing of the enhancer regulation in selected discrete brain areas of food deprived rats. Life Sci. 72:2003;2923-2930.
37. Miyoshi K. Parkinson's disease. Nippon Rinsho. 59:2001;1570-1573.
38. Myttyla V.V., Sotaniemi K.A., Vourinen J.A., Heinonen E.H. Selegiline as initial treatment in de novo parkinsonian patients. Neurology. 42:1992;339-343.
39. Nguyen T.V., Juorio A.V. Binding sites for brain trace amines. Cell. Mol. Neurobiol. 9:1989;297-311.
40. Ohta K., Ohta M., Mizuta I., Fujinami A., Shimazu S., Sato N., Yoneda F., Hayashi K., Kuno S. The novel catecholaminergic and serotoninergic activity enhancer R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane up-regulates neurotrophic factor synthesis in mouse astrocytes. Neurosci. Lett. 328:2002;205.
41. Oka T., Yasusa T., Ando T., Watanabe M., Yoneda F., Ishida T., Knoll J. Enantioselective synthesis and absolute configuration of (-)-1-(benzofuran-2-yl) -2-propylaminopentane, ((-)-BPAP), a highly potent and selective catecholaminergic activity enhancer. Bioorg. Med. Chem. 9:2001;1213-1219.
42. Parkinson Study Group Effect of (-)deprenyl on the progression disability in early Parkinson's disease. N. Engl. J. Med. 321:1989;1364-1371.
43. Parkinson Study Group Effect of tocopherol and (-)deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:1993;176-183.
44. Premont R.T., Gainetdinov R.R., Caron M.G. Following the trace of elusive amines. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9474-9475.
45. Quitkin F.M., Liebowitz M.R., Stewart J.W., McGrath P.J., Harrison W., Rabkin J.G., Markowitz J., Davies S.O. L-Deprenyl in atypical depression. Arch. Gen. Psychiatry. 41:1984;777-781.
46. Ritter J.L., Alexander B. Retrospective study of selegiline- antidepressant drug interactions and a review of the literature. Ann. Clin. Psychiatry. 9:1997;7-13.
47. Saaverda J.M. Catecholamines II. Trendelenburg U., Weiner N. Handbook of Experimental Pharmacology. 1989;181-201 Springer-Verlag, New York.
48. Sabelli A.C., Giardina W.J. Amine modulation of affective behavior. Sabelli A.C. Chemical Modulation of Brain Function. 1973;225-259 Raven Press, New York.
49. Sabelli H.C., Javaid J.I. Phenylethylamine modulation of affect: therapeutic and diagnostic implications. J. Neuropsychiatry Clin. Neurosci. 7:1995;6-14.
50. Sabelli H.C., Fawcett J., Gusovsky F., Javaid J.I., Wynn P., Edwards J., Jeffriess H., Kravitz H.J. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. Clin. Psychiatry. 47:1986;66-70.
51. Sabelli H., Fink P., Fawcett J., Tom C. Sustained antidepressant effect of PEA replacement. J. Neuropsychiatry Clin. Neurosci. 8:1996;168-171.
52. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N. Engl. J. Med. 336:1997;1216-1222.
53. Satoi M., Matsuishi T., Yamada S., Yamashita Y., Ohtaki E., Mori K., Riikonen R., Kato H., Percy A.K. Decreased cerebrosbinal fluid levels of beta-phenylethylamine in patients with Rett syndrome. Ann. Neurol. 47:2000;801-803.
54. Shimazu S., Takahata K., Katsuki H., Tsunekawa H., Tanigawa A., Yoneda F., Knoll J., Akaike A. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. Eur. J. Pharmacol. 421:2001;181-189.
55. Shimazu S., Tamashiro A., Yoneda F., Knoll J. The L-DOPA-sparing effect of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in reserpine-pretreated rats. Life Sci. 72:2003;1413-1419.
56. Shimazu S., Tanigawa A., Sato N., Yoneda F., Hayashi K., Knoll J. Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2- propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes. Life Sci. 72:2003;2785-2792.
57. Tetrud J.W., Langston J.W. The effect of (-)deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 245:1989;519-522.
58. Tom T., Cummings J.L. Depression in Parkinson's disease. Pharmacological characteristics and treatment. Drugs Aging. 12:1998;55-74.
59. Tringer L., Haits G., Varga E. The effect of L-E-250 (-L-phenyl- isopropylmethyl-propinyl-amine HCl) in depression. Leszkovszky G. V. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia. 1971;111-114 Publishing House of the Hungarian Academy of Sciences, Budapest, Hungary.
60. Usdin E., Sandler M. Trace Amines and the Brain. 1976;21-40 Marcel Dekker, New York.
61. van Nguyen T., Paterson I.A., Juorio A.V., Greenshaw A.J., Boulton A.A. Tryptamine receptors: neurochemical and electrophysiological evidence for postsynaptic and functional binding sites. Brain Res. 476:1989;85-93.
62. Varga E. Vorl ä ufiger Bericht über die Wirkung des Prparats E-250 (phenyl-isopropyl-methyl-propinylamine-chlorhydrat). Dumbovich B. III Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia. 1965;197-201 Publishing House of the Hungarian Academy of Sciences, Budapest, Hungary.
63. Varga E., Tringer L. Clinical trial of a new type of promptly acting psychoenergetic agent (phenyl-isopropylmethyl-propinylamine HCl, E-250). Acta Med. Acad. Sci. Hung. 23:1967;289-295.
64. Walker S.E., Shulman K.I., Tailor S.A., Gardner D. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J. Clin. Psychopharmacol. 16:1996;383-388.
65. Yoneda F., Moto T., Sakae M., Ohde H., Knoll B., Miklya I., Knoll J. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2- propylaminopentane, [(-)BPAP], a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Bioorg. Med. Chem. 9:2001;1197-1212.
66. Youdim M.B. Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease. J. Neural Transm. Suppl. 16:1980;157-161.